<DOC>
	<DOCNO>NCT00491491</DOCNO>
	<brief_summary>The study hypothesis addition zevalin radioimmunotherapy condition regimen give prior BEAM high-dose chemotherapy autologous stem cell transplantation patient aggressive lymphoma reduce disease recurrence rate improve overall disease-free survival .</brief_summary>
	<brief_title>Zevalin-beam Aggressive Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients CD20 positive diffuse large Bcell lymphoma confirm pathological biopsy report . 2 . Patients candidate autologous stemcell transplantation due primary refractory first relapse disease . 3 . Patients must chemosensitive disease achieve least partial response ( Cheson 2007 criterion ) last chemotherapy . 4 . Age ≥ 18 year age ≤ 70 5 . Patients adequate autologous stem cell collection transplantation ( target ≥ 2.5 x 106 CD34+ cells/kg ) . 6 . Patients must sign write informed consent . 7 . Adequate birth control fertile patient . 8 . All prior chemotherapy complete least three week study treatment . 9 . Marrow involvement le 25 % transplantation , limitation blood count ( low platelet count allow ) . 10 . Negative HIV antibody . 1 . 1 . Chemorefractory disease determine less partial response ( Cheson 2007 Criteria ) last chemotherapy . 2 . Two relapse initial response induction chemotherapy . 3 . Highgrade transformation earlier diagnosis lowgrade lymphoma . Patients `` De Novo '' Transformed DLBCL , define DLBCL lymph node biopsy discordant marrow paratrabecular small cell first diagnosis lymphoma , eligible adherent selection criterion . 4 . Bilirubin &gt; 3.0 mg/dl , transaminases &gt; 3 time upper normal limit . 5 . Creatinine &gt; 2.0 mg/dl . 6 . ECOG Performance status &gt; 2 . 7 . Uncontrolled infection . 8 . Pregnancy lactation . 9 . Abnormal lung diffusion capacity ( DLCO &lt; 40 % predict ) . 10 . Severe cardiovascular disease ; New York Heart Association ( NYHA ) Functional Classification ≥2 . 11 . Active CNS disease involvement . 12 . Presence malignancy history prior malignancy within 5 year study entry . Within 5 year , patient treat Stage I II cancer eligible provided life expectancy &gt; 5 year relation prior malignance . The 5year exclusion rule apply tonon melanoma skin tumor situ cervical cancer . 13 . Pleural effusion ascites &gt; 1 liter . 14 . Known hypersensitivity rituximab . 15 . Psychiatric conditions/disease impair ability give inform consent adequately cooperate . 16 . Prior radioimmunotherapy . 17 . Prior autologous allogeneic HSCT . 18 . Active evidence Hepatitis B C infection ; Hepatitis B surface antigen positive . 19 . Patients prior radiation lung exclude study , although mediastinal irradiation permit minimal lung treatment volume . 20 . Patients receive &gt; 500cGy radiation kidney exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>autologous stem cell transplantation</keyword>
	<keyword>radioimmunotherapy</keyword>
	<keyword>zevalin</keyword>
</DOC>